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Brief Definit ive Report
Broadly neutralizing antibodies (bNAbs) target-
ing HIV-1 are of special interest because of their 
ability to prevent and treat HIV-1 and SHIV 
infection in humanized mice and nonhuman 
primates (NHPs), respectively (Klein et al., 2012; 
Moldt et al., 2012; Barouch et al., 2013; Klein 
et al., 2013; Shingai et al., 2013). Although there 
was excellent agreement between humanized 
mice and macaques in passive protection exper-
iments (Balazs et al., 2012; Pietzsch et al., 2012; 
Shingai et al., 2013), immunotherapy of estab-
lished infection was far more effective in ma-
caques infected with SHIVAD8 or SHIVSF162P3 
than in humanized mice infected with HIV-1YU2. 
Humanized mice treated with single mAbs 
showed only a transient drop in viremia with 
rapid escape caused by selection of antibody-
resistant mutants (Klein et al., 2012; Horwitz 
et al., 2013). In contrast, passive transfer experi-
ments of single bNAbs in macaques produced 
a profound decrease in viremia (Barouch et al., 
2013; Shingai et al., 2013), and prolonged con-
trol (Barouch et al., 2013), with only occasional 
viral escape (Shingai et al., 2013). This disparity 
could be due in part to the host immune sys-
tem, which is present in the macaques but de-
fective in humanized mice. However, how the 
host immune system might enhance passive an-
tibody therapy is not known. Here, we investigate 
the role of the autologous antibody response in 
suppressing the emergence of viral bNAb escape 
variants in vivo.
RESULTS AND DISCUSSION
Simultaneous administration of three bNAbs 
(tri-mix) targeting the CD4-binding site (CD4bs; 
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Antibody-mediated immunotherapy is effective in humanized mice when combinations of 
broadly neutralizing antibodies (bNAbs) are used that target nonoverlapping sites on the 
human immunodeficiency virus type  (HIV-) envelope. In contrast, single bNAbs can 
control simian–human immunodeficiency virus (SHIV) infection in immune-competent 
macaques, suggesting that the host immune response might also contribute to the control 
of viremia. Here, we investigate how the autologous antibody response in intact hosts can 
contribute to the success of immunotherapy. We find that frequently arising antibodies 
that normally fail to control HIV- infection can synergize with passively administered 
bNAbs by preventing the emergence of bNAb viral escape variants.
© 2014 Klein et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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To determine whether HIV-1 can escape from all three 
antibodies when they are administered sequentially, we treated 
HIV-1YU2–infected mice with bNAbs starting with PG16 
alone, and added 3BNC117 after 14 d, and 10–1074 after 28 d 
(Fig. 1 A). We found a transient reduction (0.18 log10 to 0.78 
log10) of the viral load shortly after each antibody was admin-
istered, followed by rapid rebound to baseline viremia (day 
42; +0.14 log10 compared with day 0; Fig. 1 A). Thus, sequen-
tial antibody administration differs from co-administration of 
the same tri-mix in that sequential therapy fails to control 
viral replication.
3BNC117; Scheid et al., 2011), the V1/V2-loop (PG16; 
Walker et al., 2009), and the V3-stem (10–1074; Mouquet, 
2012) effectively suppresses viremia in HIV-1YU2–infected 
humanized mice without the emergence of viral escape vari-
ants (Horwitz et al., 2013). The humanized mice used in the 
experiments are NOD Rag1/ IL2RNULL mice that are 
reconstituted with human hematopoietic stem cells. These 
mice support the development of human T lymphocytes that 
can be infected with HIV-1 but they do not produce signifi-
cant antibody responses to the pathogen (Baenziger et al., 
2006; Klein et al., 2012).
Figure . Sequential treatment of HIV-YU2–
infected humanized mice with bNAbs selects for 
triple-escape mutants. (A) HIV-1YU2–infected mice were 
sequentially treated with PG16 (orange), PG16, and 
3BNC117 (green) and finally with the tri-mix consisting 
of PG16, 3BNC117, and 10–1074 (blue) as indicated. 
Graph shows the log10 change in viral RNA copies in 
plasma plotted on the y-axis and time in days after start-
ing treatment on the x-axis. The red line shows the mean 
of changes in viral load. Individual mice IDs are listed at 
the right. (B) gp120 envelope sequence analysis before 
and after 14, 28, and 42–49 d of treatment revealed the 
emergence of HIV-1YU2 escape variants at the respective 
target sites of the bNAbs (i.e., PNGS at position N160 for 
PG16; 280–282 and 458 for 3BNC117; PNGS at position 
N332 for 10–1074). Each dotted line represents an inde-
pendent sequence and changes to gp120YU2 are shown  
in bold. Red letters and gray highlights indicate regions 
corresponding to known escape sites as identified in 
previous monotherapy experiments (Klein et al., 2012; 
Horwitz et al., 2013). Residues in HIV-1YU2 (top) were 
numbered according to HXBc2 (bottom). Presented  
data were obtained from five treated mice in a single 
experiment, and sequence information was retrieved  
and analyzed from at least three mice at each indicated 
time point.
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antibody-resistant HIV-1YU2 escape variants (Fig. 1 B). For 
example, 14 d after starting PG16 therapy, all gp120 sequences 
analyzed carried mutations at position N160 or T162 that re-
move the epitope targeted by PG16 (Fig. 1 B). Sequential ad-
dition of 3BNC117 and 10–1074 selected for viral escape 
Failure to suppress viremia with sequential tri-mix admin-
istration suggested that this form of therapy selects for viral 
variants that are resistant to all three antibodies (Fig. 1 A). Con-
sistent with this idea, viral envelope sequence analysis at day 
0, 14, 28, and 42–49 revealed sequential development of specific 
Figure 2. Infection of humanized mice with  
HIV-YU2 triple mutant (HIV-YU2TM2). (A) Viral loads  
in humanized mice infected with WT HIV-1YU2 (blue) and 
HIV-1YU2TM2 (green) at day 34 after infection. P-value was 
determined using a two-sided Mann-Whitney U test. 
**, P < 0.001. Plot shows data of 30 infected mice of 1 
representative experiment of 2 performed. (B) Graph 
shows viral RNA copies/ml (y-axis) versus days after in-
fection (x-axis) for HIV-1YU2TM2–infected humanized mice. 
Each black line represents a single mouse, and the red 
line represents the geometric mean. (C) env sequence 
analysis of individual mice that are shown in (B). Time of 
sequence analysis is indicated in days after infection. 
(D) Tri-mix (PG16, 3BNC117, 10–1074) therapy in mice 
infected with HIV-1YU2 (left) and HIV-1YU2TM2 (right). 
Changes in viral load in log10 (y-axis) plotted against 
days after infection (x-axis) compared with baseline (day 0). 
Each black line represents a single mouse and the red 
line illustrates the mean. Treatment response in mice 
infected with HIV-1YU2 or HIV-1YU2TM2 was analyzed in 
parallel in a single experiment and each group consisted 
of at least five individual mice (D).
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(Zolla-Pazner, 2005; Scheid et al., 2009). To determine whether 
these antibodies with limited activity (tier-1 strains only; here 
termed tier-1 neutralizing antibodies) are active against viruses 
that carry bNAb escape mutations, we assayed a panel of 34 tier-1 
neutralizing mAbs directed against the V2 or the V3 loop, the 
CD4bs, the CD4-induced site (CD4i), and gp41 (Scheid et al., 
2009; Pietzsch et al., 2010; Mouquet et al., 2011). Each of these 
antibodies was tested against WT HIV-1YU2 and bNAb-resistant 
variants of HIV-1YU2 with mutations that naturally arose in 
in vivo experiments (single mutations: N160K, N332K, and 
N280Y; HIV-1YU2 triple mutations: TM1-3; Fig. 4 B; Klein 
et al., 2012; Horwitz et al., 2013). Only one of the tier-1 neu-
tralizing antibodies showed activity against the WT HIV-1YU2 at 
a very high concentration (IC50 = 93 µg/ml; Fig. 4 B). In con-
trast, three V2 loop-, four V3 loop-, two CD4bs-, and one CD4i-
directed antibodies showed activity against the HIV-1YU2 mutant 
viruses with IC50s as low as 0.5 µg/ml (Fig. 4 B). The three V2 
variants that carry mutations in all three antibody target sites 
(Fig. 1 B; Klein et al., 2012; Horwitz et al., 2013). Thus, se-
quential triple bNAb therapy selects for HIV-1YU2 variants 
that are resistant to all three bNAbs.
To determine whether tri-mix resistant HIV-1YU2 retains 
infectivity we compared infection with WT HIV-1YU2 and a 
variant harboring the N160K, N332K, and G458D muta-
tion (HIV-1YU2TM2). 34 d after infection, HIV-1YU2– and 
HIV-1YU2TM2–infected mice showed geometric mean viral 
loads of 4.2 log10 and 5.42 log10, respectively (P = 0.0003; 
Fig. 2 A). Viremia was long lasting in HIV-1YU2TM2–infected mice 
(Fig. 2 B) and in most cases the N160K, N332K, and G458D 
mutations were maintained even in the absence of antibody 
selection pressure (Fig. 2 C). Finally, HIV-1YU2TM2–infected 
mice were resistant to tri-mix therapy (Fig. 2 D). We con-
cluded that HIV-1YU2 can escape from sequential tri-mix ther-
apy in vivo without measurable loss of infectivity or impaired 
viral fitness in humanized mice.
To determine whether chronically SHIVAD8-infected NHPs 
or HIV-1–infected humans harbor antibodies that might 
neutralize bNAb-resistant variants, we assayed plasma/serum 
samples for neutralizing activity against escape variants in vitro. 
Plasma samples from chronically SHIVAD8-infected macaques 
(Shingai et al., 2012, 2013) were tested against WT SHIVAD8 
and SHIVAD8 variants. The SHIVAD8 variants carried either 
an N332K mutation (SHIVAD8N332K) that rendered the virus 
resistant to the bNAb 10–1074 or the G458D mutation 
(SHIVAD8G458D) that strongly reduced (200-fold) sensitivity to 
the bNAb 3BNC117. In addition, we included an SHIVAD8 
variant that harbored both mutations (N332K-G458D; 
SHIVAD8DM). Although plasma from 16 SHIVAD8-infected 
macaques showed varying levels of neutralizing activity against 
the WT virus SHIVAD8 (Fig. 3 A; ID50), a significant increase 
in neutralizing activity was detected for bNAb-resistant vari-
ants that carried the G458D and the double N332K-G458D 
mutation (Fig. 3 B). Moreover, this effect was not specific for 
SHIVAD8 since even more striking differences were observed 
for WT HIV-1YU2 and HIV-1YU2 triple bNAb escape mutants 
TM1 (N160K, N332K, and N280Y) and TM2 (N160K, N332K, 
and G458D; Fig. 3, A and B). Thus, macaques chronically in-
fected with SHIVAD8 frequently carry antibodies that neutral-
ize the bNAb escape mutants studied.
To determine whether chronically infected humans also 
have similar antibodies, we tested a collection of 17 serum 
samples from HIV-1–infected individuals. Similar to macaques, 
purified IgGs from infected humans showed little or no neu-
tralization against WT HIV-1YU2, but increased activity against 
HIV-1YU2TM1 (Fig. 4 A; mean percentage of neutralization at 
100 µg/ml total IgG: 2.5 vs. 23.9; P = 0.0004, two-sided Mann-
Whitney U test). Thus, most humans infected with HIV-1 carry 
antibodies that have demonstrable in vitro neutralizing activity 
against the studied bNAb-resistant variants of HIV-1YU2.
Individuals infected with HIV-1 develop up to 60 different 
clones of B cells, producing antibodies that have neutralizing 
activity against easy to neutralize (tier-1) HIV-1 strains but have 
weak or no activity against more resistant tier-2 primary isolates 
Figure . Increased neutralizing NHP serum activity against bNAb 
escape variants. (A) Table shows serum neutralization (ID50) of NHPs 
after established infection with SHIVAD8 (days post infection [PI] as indi-
cated in NHP ID). Neutralizing activity was measured against SHIVAD8 WT 
(gray), N332K, and G458D single mutants (blue), as well as an SHIVAD8 
double mutant (double; N332K and G458D, blue). NHP plasma was also 
tested against WT HIV-1YU2 (gray) and HIV-1YU2TM1 (N160K, N332K, N280Y, 
blue) and HIV-1YU2TM2 (TM2; N160K, N332K, G458D, blue). (B) Bars repre-
sent the mean and SEM of the respective data shown in A. Statistical 
analysis was performed using a Friedman test followed by Dunn multiple 
comparison test. Significant differences compared with WT are indicated 
by asterisks (*, P < 0.05; **, P < 0.001; ***, P < 0.0001). All neutralizing 
activities were measured in duplicate.
 o
n
 N
ovem
ber 17, 2014
jem.rupress.org
D
ow
nloaded from
 
Published November 10, 2014
JEM  of 2
Br ief Definit ive Repor t
To determine whether antibodies that neutralize bNAb 
escape variants can also be elicited by vaccination, we analyzed 
plasma from NHPs immunized with YU2 gp140-F trimers 
(Sundling et al., 2010). Although plasma samples from the 
vaccinated animals showed little or no neutralizing activity 
against HIV-1YU2 (WT; Fig. 4 C), there was a significant increase 
loop-directed antibodies were active against HIV-1YU2N332K, 
HIV-1YU2TM1, and HIV-1YU2TM2. The four V3 loop-directed an-
tibodies showed activity against HIV-1YU2N280Y, HIV-1YU2N160K, 
HIV-1YU2N332K, as well as all three HIV-1YU2TMs. Finally, at least 
one of each of the antibodies targeting CD4bs and CD4i was 
active against the HIV-1YU2TMs in vitro (Fig. 4 B).
Figure . Increased neutralizing activity against 
bNAb escape variants. (A) Graph shows percentage of 
neutralizing activity (y-axis) of purified IgG (µg/ml; 
x-axis) from 17 serum samples of HIV-1–infected indi-
viduals measured against WT HIV-1YU2 (left) or HIV-1YU2TM1 
(right; N160K, N332K, N280Y). Individual samples and 
the mean are shown in black and red, respectively.  
(B) Table shows the IC50 antibody concentrations (µg/ml) 
for the indicated antibodies against HIV-1YU2 (WT),  
HIV-1YU2TM1 (TM1; N160K, N332K, N280Y), HIV-1YU2TM2 
(TM2; N160K, N332K, G458D), HIV-1YU2TM3 (TM3; N162I, 
N332K, N279K), HIV-1YU2N160K (N160K), HIV-1YU2N332K 
(N332K), and HIV-1YU2N280Y (N280Y). The epitopes targeted 
by the antibodies are indicated on the left and in pa-
rentheses. (C) Values reflect ID50 neutralization titers 
against HIV-1YU2 (WT), HIV-1YU2TM1 (TM1), and HIV-1YU2TM2 
(TM2) for plasma samples from two macaques (F124, 
F128) before and after immunization with gp140-F (YU2). 
(D) IC50 concentrations (µg/ml) against HIV-1YU2 and  
HIV-1YU2 mutants for six randomly selected V3 loop-
directed mAbs obtained from gp140-F immunized  
macaques as described in B. Neutralization activity is 
color-coded and IC50-values of mAbs (B are D) are high-
lighted in red (<2 µg/ml), orange (2–20 µg/ml), yellow 
(>20 µg/ml), and white (IC50 is not reached at concentra-
tion tested). ID50-titers of plasma are highlighted in red 
(>400), orange (200–400), yellow (50–200), and white 
(<50). Neutralizing activities of plasma samples, anti-
bodies, or purified IgGs were measured in duplicate.
 o
n
 N
ovem
ber 17, 2014
jem.rupress.org
D
ow
nloaded from
 
Published November 10, 2014
 of 2 Common anti–HIV-1 antibodies target viral escape variants | Klein et al.
mice (2 animals) carried mutations in the same region (Fig. 6 B, 
bottom). In the case of HIV-1YU2–infected mice treated with 
1–79, we also detected mutations in the V3 crown in some 
but not all of the sequences in the 3 animals we analyzed, in-
dicating incomplete selection (Fig. 6 C). In contrast, all se-
quences obtained from HIV-1YU2TM2–infected mice treated 
with 1–79 harbored the same K305R mutation (Fig. 6 C).
HIV-1YU2TM2 is an engineered virus that carries bNAb 
escape mutations that naturally occurred in mice treated with 
single antibodies (Klein et al., 2012; Horwitz et al., 2013). How-
ever, it is not a naturally arising strain that might also contain 
compensatory mutations as part of a heterogeneous swarm. 
To determine whether combination immunotherapy with a 
bNAb and a tier-1 neutralizing antibody can delay or suppress 
emergence of resistant HIV-1 variants during an established 
infection with a naturally arising strain, we infected human-
ized mice with HIV-1YU2 (WT) and treated them with the 
bNAb 10–1074 alone (Fig. 7 A) or in combination with one 
of the tier-1 neutralizing antibodies 10–188 (Fig. 7 B) or 1–79 
(Fig. 7 C). Notably, the humanized mice used in our experi-
ments are unable to make a significant humoral immune 
response to the HIV-1 envelope, and therefore lack any autol-
ogous neutralizing antibodies (Baenziger et al., 2006; Klein 
in neutralizing activity against the HIV-1YU2 triple mutants 
(HIV-1YU2TM1, HIV-1YU2TM2; Fig. 4 C). To determine whether 
macaque antibodies recognizing the V3 loop might account 
for this activity, we tested 6 different anti-V3 mAbs isolated 
from these immunized macaques against WT HIV-1YU2, 
HIV-1YU2N280Y, HIV-1YU2N160K, HIV-1YU2N332K, and two 
HIV-1YU2TMs (Fig. 4 D). 2 of the 6 antibodies had low levels of 
activity against HIV-1YU2 (WT; IC50s of 33.8 and 49.6 µg/ml), 
whereas the other four did not reach an IC50 when measured 
up to a concentration of 50 µg/ml. In contrast, 5 out of these 6 
V3 loop-directed antibodies showed activity against the 
HIV-1YU2 single mutants. Moreover, neutralization activity 
was strongly increased against both HIV-1YU2TMs as reflected 
by IC50s in the range of 1 µg/ml (Fig. 4 D). Thus, although 
tier-1 neutralizing human and macaque anti–HIV-1 antibod-
ies do not neutralize WT HIV-1YU2, they are active against 
bNAb escape variants in TZM-bl assays in vitro.
Of the tested human tier-1 neutralizing antibodies, 10–188 
and 1–79 demonstrated the best neutralizing activity against 
the triple mutated HIV-1YU2 (Fig. 4 B). Both antibodies 
recognize the crown of the V3 loop. Notably, 10–188 and 
1–79 bind to different regions of the V3 loop: 1–79 targets 
the hydrophobic V3 core at aa 307, 309, and 317 (CRA-
DLE-type; Burke et al., 2009; Almond et al., 2010; Jiang 
et al., 2010; and unpublished data) and 10–188 targets the V3 
-turn at aa 312–314 (LADLE-type; Burke et al., 2009). To 
determine, whether similar antibodies are present in NHPs 
chronically infected with SHIVAD8, we measured reactivity of 
plasma samples against selected peptides by ELISA (Fig. 5; 
Totrov et al., 2010). All tested NHP sera showed activity 
against both peptides, demonstrating the presence of CRA-
DLE- and LADLE-type antibodies in SHIVAD8-infected 
NHPs (Fig. 5).
To examine the possibility that HIV-1–directed tier-1 
neutralizing antibodies can actively suppress viremia in vivo, 
we infected humanized mice with HIV-1YU2 (WT) or with 
HIV-1YU2TM2. Infected mice were treated with either of the 
tier-1 neutralizing human V3 loop-directed antibodies 10–188 
or 1–79. Although only a small effect on the viral load was 
detected in HIV-1YU2–infected mice (Fig. 6 A, left), a reduc-
tion in viremia was observed in mice infected with the mutant 
virus HIV-1YU2TM2 (Fig. 6 A, middle and right). We conclude 
that the tier-1 neutralizing anti-V3 loop antibodies 10–188 
and 1–79 do not alter the viral load in HIV-1YU2–infected 
mice, but can suppress HIV-1YU2TM2 infection in vivo.
To determine whether 10–188 and 1–79 exerted selec-
tive pressure on HIV-1YU2 and/or HIV-1YU2TM2, we cloned 
and sequenced cDNA encoding gp120 from HIV-1YU2– and 
HIV-1YU2TM2–infected mice treated with these antibodies. 
Although 10–188 showed little activity against HIV-1YU2  
in vitro (IC50 93 µg/ml) and had no measurable effect on the 
viral load in HIV-1YU2–infected mice, 2 out of the 4 mice 
showed mutations in the -turn in the crown of the V3 loop, 
which is the epitope targeted by 10–188 (Zolla-Pazner and 
Cardozo, 2010; Mouquet et al., 2011; Fig. 6 B, top). In addition, 
all gp120 sequences analyzed from HIV-1YU2TM2–infected 
Figure . Presence of V-specific antibodies in plasma of SHIVAD8-
infected NHPs. Values reflect OD405 measurements (values >0.3 were 
considered positive). PI, post infection (days). mAbs were measured at  
10 µg/ml. Plasma samples were measured at a titer of 1:100. ID50 titers of 
plasma are highlighted in red (>2.5), orange (1–2.5), and yellow (0.3–1).
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Figure . Suppression of HIV-YU2TM2 but not HIV-YU2 viremia by V-loop antibodies 0–88 and –9. (A, left and middle) Graphs show changes in viral 
load in response to 10–188 or 1–79 treatment in log10 (y-axis) plotted against days after infection (x-axis) compared with baseline (day 0) for mice infected with HIV-1YU2 
or HIV-1YU2TM2. Each black line represents a single mouse, and the red line illustrates the mean. Blue colored symbols indicate a viral load measurement below 200 copies/ml.  
(A, right) Statistical analysis to determine group differences between HIV-1 YU2 (green) and HIV-1YU2TM2 (orange) using repeated measures ANOVA; 10–188, P = 0.003; 
1–79, P = 0.032. (B and, C) gp120 sequences obtained from HIV-1YU2– or HIV-1YU2TM2–infected mice treated with 10–188 (B) or 1–79 (C) between days 14 and 28. Residues 
in HIV-1YU2 (top) were numbered according to HXBc2 (bottom). Treatment response of 10–188 and 1–79 in mice infected with HIV-1YU2 or HIV-1YU2TM2 was analyzed in a 
single experiment in which each group consisted of at least four individual mice and sequence data were obtained from at least two mice per group.
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make significant contributions to control HIV-1 infection 
when combined with potent bNAbs in vivo.
Most individuals infected with HIV-1 develop antibodies 
that neutralize autologous but not primary heterologous viral 
strains (Doria-Rose et al., 2009; Simek et al., 2009). As a result 
of the rapid rate of viral evolution in the host, the effect of 
these antibodies on effectively controlling viremia is limited 
(Schmitz et al., 2003; Miller et al., 2007; Gaufin et al., 2009a,b; 
Huang et al., 2010). Nevertheless, these antibodies put selective 
pressure on HIV-1 as indicated by the emergence of antibody-
resistant escape variants (Wei et al., 2003). Escape from tier-1 
neutralizing antibodies frequently involves changes that indirectly 
conceal the epitope (Ly and Stamatatos, 2000; Wei et al., 2003; 
Pinter et al., 2004; Blish et al., 2008; Bunnik et al., 2008; 
et al., 2012). In contrast to monotherapy with any of the three 
antibodies alone (Figs. 6 A and 7 A), both combinations pro-
duced a prolonged and sustained drop in viremia (Fig. 7, 
B–D). Moreover, the combination of 10–1074 and 1–79 con-
tinued to suppress viremia below the limit of detection, with 
no viral escape during 6 wk of therapy (Fig. 7 C). Escape from 
10–1074 monotherapy was associated with N332K/S in 6 
out of 6 mice analyzed (Fig. 7 E). When rebound occurred 
with the combination of 10–1074 and 10–188, it was associ-
ated with selection of mutations in both the 10–1074 and 
10–188 target sites at position 332 and the -turn of the V3 
crown (position 312–315), respectively (Fig. 7 F).
We conclude that tier-1 neutralizing antibodies with little 
demonstrable activity against primary isolates in vitro can 
Figure . Synergy between tier- neu-
tralizing V antibodies (0–88 or –9) 
and a bNAb (0–0) in controlling 
viremia in vivo. (A–D) Graphs show changes 
in viral load (in log10; y-axis) in HIV-1YU2–
infected mice plotted against days after start-
ing antibody treatment (x-axis) with 10–1074 
alone (A), the combination of 10–1074 and 
10–188 (B), and the combination of 10–1074 
and 1–79 (C). Individual mice are plotted as 
black lines, and the mean is shown in red. 
Blue symbols indicate a viral load measure-
ment below 200 copies/ml. (D) Changes of 
log10 viral loads (mean and SEM) of mice 
treated with 10–1074 (gray), 10–1074 +  
10–188 (blue), and 10–1074 + 1–79 (green). 
Significant differences between treatment 
groups were determined by using repeated 
measures ANOVA with a Bonferroni post-hoc 
test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001). 
Animals that died before day 42 after treat-
ment start were excluded from statistical 
analysis. (E) gp120 sequences 14–28 d after 
the start of 10–1074 treatment. (F) gp120 
sequences 35–49 d after the start of treat-
ment with 10–1074 and 10–188. Residues in 
HIV-1YU2 (top) were numbered according to 
HXBc2 (bottom). Treatment combinations 
were analyzed on 6–10 animals per group in a 
single round experiment. Sequence data were 
obtained from at least five individual mice of 
each analyzed group.
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Allergy and Infectious Disease (NIAID) facility and cared for in accordance 
with standards of the American Association for Accreditation of Laboratory 
Animal Care (AAALAC) in AAALAC-accredited facilities. All animal proce-
dures were performed according to NIAID animal protocol LMM32, ap-
proved by the Institutional Animal Care and Use Committees of NIAID/NIH. 
The animals used for immunizations were housed at the AAALAC-accredited 
Astrid Fagraeus Laboratory animal facility in Stockholm in compliance with 
the guidelines of the Swedish Board of Agriculture. Isolation of mAbs from 
NHPs was performed essentially as previously described (Sundling et al., 
2012a) but by sorting for total Env-specific memory B cells and using opti-
mized primers for amplification of NHP VDJ sequences (Sundling et al., 
2012b). For antibody expression, equal amounts of heavy- and light-chain 
plasmid DNAs were transfected into FreeStyle 293F cells and the secreted 
IgGs were purified by protein A–Sepharose columns (GE Healthcare). The 
specificities of these V3 loop-directed antibodies were determined by ELISA 
binding analyses using a set of different YU2 Env probes.
Humanized mice. NOD Rag1/ IL2RNULL mice were humanized with 
hematopoietic stem cells (HSCs), as previously described (Klein et al., 2012). 
In brief, human fetal livers were procured from Advanced Bioscience Re-
sources, Inc. and HSCs were isolated using a CD34+ isolation kit (Stem Cell 
Technologies, Inc.). Mice (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ) were ob-
tained from The Jackson Laboratory and bred and maintained at the Com-
parative Bioscience Center of The Rockefeller University. Between 1–5-d-old 
mice were irradiated with 100 cGy and injected with 2 × 105 human HSCs. 
HSCs used to reconstitute the mice were obtained from human fetal liver 
tissues of 12 different donors. In the experiments shown, up to 12 humanized 
mice shared the same donor. Engraftment was evaluated by FACS analysis of 
the peripheral blood as previously described (Klein et al., 2012) and mice 
with successful reconstitution of human lymphocytes were challenged with 
HIV-1YU2 or HIV-1YU2TM2. All experiments were performed under approval 
of the Institutional Review Board and the Institutional Animal Care and Use 
Committee of The Rockefeller University.
HIV-1 infection. HIV-1YU2 and HIV-1YU2TM2 were produced by transiently 
transfecting HEK 293T/17 cells using a construct consisting of HIV-1NL4/3 
backbone carrying the HIV-1YU2 envelope (Zhang et al., 2002). HIV-1YU2TM2 
harbors the mutations N160K, N332K, and G458D that were introduced by 
site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis 
kit (Agilent Technologies). The concentration of the virus was determined by 
measuring p24 using the Alliance HIV-1 p24 Antigen ELISA kit (Perkin-
Elmer). Humanized mice were infected by intraperitoneal injection of 
HIV-1YU2 or HIV-1YU2TM2 viral supernatant containing 110 ng of p24.
Production and administration of mAbs. For mouse treatment experi-
ments we used the following mAbs: PG16 (V1/V2; Walker et al., 2009), 
10–1074 (V3-stem; Mouquet et al., 2012), 3BNC117 (CD4bs; Scheid et al., 
2011), 10–188 (V3-crown; Mouquet et al., 2011), and 1–79 (V3-crown; 
Scheid et al., 2009). With the exception of 3BNC117, all antibodies were 
produced by transiently transfected HEK 293-6E cells with equal amounts of 
immunoglobulin heavy and light chain expression vectors. After 7 d, the su-
pernatant was harvested and antibodies were concentrated by ammonium 
sulfate precipitation. IgG was purified with Protein G–Sepharose 4 Fast Flow. 
3BNC117 was produced in CHO cells by Celldex Therapeutics, Inc. All an-
tibodies were filtered (Ultrafree-CL Centrifugal Filters, 0.22 µm; Millipore) 
and administered s.c. to humanized mice. For treatment of HIV-1–infected 
mice, 1 mg (each) of 3BNC117, PG16, and 10–1074 was injected as loading 
dose followed by 0.5 mg of each antibody/mouse twice a week. 10–188 and 
1–79 were injected at 4 mg/mouse for the loading dose followed by 2 mg/
mouse twice a week.
HIV-1 plasma viral load. Plasma viral load in HIV-1–infected humanized 
mice was determined as previously described (Klein et al., 2012).
HIV-1 envelope glycoprotein sequence analysis. Total RNA from 100 µl 
EDTA-plasma was extracted using the MinElute Virus Spin kit (QIAGEN) 
Bosch et al., 2010; O’Rourke et al., 2010). For example, the 
glycan at position N332 can shield the V3 loop from tier-1 
neutralizing anti-V3 loop antibodies, but does not alter the 
antibody target sequence directly (Wei et al., 2003; McCaffrey 
et al., 2004). Similarly, glycans at position N276 or N301 can 
shield the CD4bs from tier-1 neutralizing anti-CD4bs anti-
bodies (Koch et al., 2003; McGuire et al., 2013). These changes 
are often favored over direct changes in the target site that 
might interfere with viral fitness. For example, a glycan can be 
added to shield the V3 loop without reducing infectivity. This 
shielding mechanism appears to be preferred over escape mu-
tations in the highly conserved crown of the V3-loop that 
could interfere with co-receptor binding and alter viral fitness 
(Zolla-Pazner and Cardozo, 2010). However, the same gly-
cans that shield V3 also make important contributions to the 
epitopes of some of the most potent bNAbs, such as 10–1074 
or PGT121 (Walker et al., 2011; Mouquet et al., 2012). These 
antibodies have profound effects on viremia in NHPs but less 
so in immune compromised humanized mice when used as a 
single reagent (Klein et al., 2012; Barouch et al., 2013; Shingai 
et al., 2013; Fig. 7 A). Our data suggest that one of the reasons 
that escape from 10–1074 or PGT121 immunotherapy in 
macaques is difficult might be because the autologous anti-
bodies, which are present in macaques but not in humanized 
mice, prevent escape by the N332 mutation. Interestingly, several 
of the 10–1074-escape variants in SHIVAD8-infected NHPs 
carried a mutation that removes the potential N-linked gly-
cosylation site (PNGS) at position 332 but also generated a 
new PNGS at position 334 (Shingai et al., 2013). Therefore, 
the glycan was shifted from N332 to N334, allowing escape 
from 10–1074 as well as retaining a glycan at the V3-stem that 
is likely to protect the V3-loop from autologous antibodies.
Our experiments indicate that HIV-1 infection is in part 
more readily controlled during immunotherapy in immuno-
competent hosts because escape from bNAbs can create holes 
in the glycan shield that render the virus susceptible to other-
wise ineffective autologous antibodies that are present in nearly 
all infected individuals. Thus, although antibodies with tier-1 
neutralizing activity, such as V3 loop-directed monoclonals 
(Hioe et al., 2010), generally display weak and sporadic neu-
tralizing activity against most tier-2 viruses, they can effectively 
synergize with bNAbs in anti–HIV-1 immunotherapy.
MATERIALS AND METHODS
Human samples. Serum samples from HIV-1–infected individuals were 
collected under informed consent and in accordance with the Institutional 
Review Board (IRB; protocol number 09–281, University of Cologne, Co-
logne, Germany). All samples were heat-inactivated for 1 h at 56°C and the 
IgG fraction was purified with Protein G–Sepharose 4 Fast Flow (GE Health-
care). Sterile filtration and buffer exchange to PBS was performed for all 
IgGs before testing for neutralizing activity.
Nonhuman primate samples. Plasma samples were obtained from non-
human primates (NHPs; Macaca mulatta) 90–198 wk after infection with 
SHIVAD8 (Shingai et al., 2012, 2013) or from uninfected NHPs (Macaca 
mulatta) before and after immunization with soluble YU2 gp140-F trimers 
(Yang et al., 2002), as previously described (Sundling et al., 2010). SHIVAD8–
infected macaques were housed in a biosafety level 2 National Institute of 
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